ZTS Stock Analysis — Zoetis
Sector: Healthcare
AI Verdict
Zoetis is cheap for the growth you're getting, but the market is pricing in skepticism about its moat or execution after a -50.55% drawdown.
Competitive Moat
Zoetis develops, manufactures, and markets animal health medicines and vaccines, benefiting from regulatory barriers and entrenched relationships with veterinarians and livestock producers. Its broad portfolio and global distribution network create high switching costs for customers reliant on consistent supply and product efficacy.
Summary
Zoetis trades at just 10.6x next year's earnings despite analysts expecting 17.2% EPS growth.
Where It Stands
The stock is down -50.55% over the past year, with an RSI of 56.2 indicating a neutral momentum, and trades at a forward P/E of 10.6x versus the healthcare sector median of 22x.
Key Metrics
- RSI: 56.2 — Neutral
- Trailing P/E: 12.5x
- Forward P/E: 10.6x
- PEG Ratio: 0.73
- Earnings Growth: +0.2%
- Revenue Growth: +0.0%
- Market Cap: $31.3B
- Dividend Yield: 0.02%
- 1-Year Return: -50.55%
- 52-Week High: $155.15
- 52-Week Low: $71.00
Analyst Consensus
12 Buy · 12 Hold · 0 Sell (24 analysts)
Bull Case
With forward EPS growth projected at 17.2% and a forward P/E of only 10.6x, you're getting double-digit growth at less than half the sector's typical multiple.
Bear Case
If the P/E multiple were to compress further to 8x (below even current levels), the stock could lose another 25% from here, especially if growth disappoints.
Catalyst to Watch
Watch for upcoming earnings reports—if Zoetis delivers on the 17.2% EPS growth forecast, it could trigger a re-rating closer to sector norms.